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Toll-like receptors (TLRs) are key players in the pathogenesis of inflammatory conditions including coronary arterial disease
(CAD). They are expressed by a variety of immune cells where they recognize pathogen-associated molecular patterns (PAMPs).
TLRs recruit adaptor molecules, including myeloid differentiation primary response protein (MYD88) and TIRF-related adaptor
protein (TRAM), to mediate activation of MAPKs and NF-kappa B pathways. They are associated with the development of
CAD through various mechanisms. TLR4 is expressed in lipid-rich and atherosclerotic plaques. In TLR2−/− and TLR4−/− mice,
atherosclerosis-associated inflammation was diminished. Moreover, TLR2 and TLR4may induce expression ofWnt5a in advanced
staged atheromatous plaque leading to activation of the inflammatory processes. TLR9 is activated by CpG motifs in nucleic
acids and have been implicated in macrophage activation and the uptake of oxLDL from the circulation. Furthermore, TLR9 also
stimulates interferon-𝛼 (INF-𝛼) secretion and increases cytotoxic activity of CD4+ T-cells towards coronary artery tunica media
smooth muscle cells. This review outlines the pathophysiological role of TLR2, TLR4, and TLR9 in atherosclerosis, focusing on
evidence from animal models of the disease.
1. Introduction
The immune system is an integral component of body defense
mechanisms. It is also a fundamental culprit in the patho-
genesis of atherosclerosis, a chronic vascular disease that
underlies the development of circulatory problems includ-
ing coronary artery disease and cerebrovascular disease. In
these scenarios, atherosclerosis runs a silent asymptomatic
course, until stenosis or plaque rupture with superimposed
thrombosis manifests clinically as stroke, myocardial infarc-
tion (MI), or death. Atherosclerosis involves a chronic and
subclinical inflammatory process, initiated by endothelial
damage and activation [1]. Subsequently, an elaborate cascade
of steps involving various signaling molecules and leukocyte
activation and migration follows, leading to the formation
of atherosclerotic plaques. This complex process involves
extensive interplay between various elements of the innate
and adaptive immune systems.
The innate immune system constitutes the first line
of defense against pathogens and is highly conserved and
universal from an evolutionary perspective [2]. Central to the
function of innate immunity is the recognition of pathogen-
associated molecular patterns (PAMPs) or disease-associated
molecular patterns (DAMPs) by immune-competent cells,
such as tissue macrophages and endothelial cells. PAMPs
are molecules of microbial origin, and DAMPs are endoge-
nous molecules that normally are sequestered and become
released in response to cell injury or endogenous stress
signals, such as heat shock proteins (HSPs) [3]. PAMPs and
DAMPs are recognized by a number of pattern recognition
receptors (PRRs) expressed on sentinel immune cells, which
can trigger inflammatory and adaptive immune reactions.
Toll-like receptors (TLRs) constitute a major subgroup of
pattern recognition receptors [4]. They were first identi-
fied in Drosophila mutants that exhibited susceptibility to
fungal infections [5]. Subsequently, the human and murine
homologs of Toll were identified, and studies showed their
essential role in mediating the immune response against
bacterial lipopolysaccharide (LPS) [6, 7].
Toll-like receptors are part of interleukin-1 receptor/toll-
like receptor superfamily. They possess an extracellular
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N-terminal ligand-recognition domain with leucine-rich
repeats and a cytoplasmic carboxyl terminal tail with toll/
interleukin-1 receptor (TIR) signaling domains.The extracel-
lular leucine-rich domain binds to PAMPs and forms homo-
or heterodimers with other TLRs [8]. Vertebrate TLRs are
grouped into six subfamilies based on sequence homology,
and their structure has been extensively described elsewhere
[9, 10]. At least thirteen mammalian TLRs are known, and
these are expressed either on cell surfaces, where they bind
microbialmembrane components (TLR1, TLR2, TLR4, TLR5,
andTLR6) or endosomally (TLR11, TLR12, andTLR13) where
they recognize microbial nucleic acids (TLR3, TLR7, TLR8,
and TLR9).
TLRs are intimately tied to the process of atheroma for-
mation. TLR4 is expressed in human coronary plaques, and
that baseline TLR4 macrophage expression is upregulated by
oxidized LDL (oxLDL) [11]. TLR2 and TLR4 are expressed by
macrophages, neutrophils, and dendritic cells and have been
implicated in the development of coronary artery disease
(CAD) through activation of NF-𝜅B pathways [12]. Further-
more, investigators have suggested that the phenomenon
of molecular mimicry may be at play at activating innate
immune pathways leading to atherosclerosis. TLR4 recog-
nizes chlamydial antigens, and some studies have demon-
strated a link between Chlamydia pneumoniae infection and
atherothrombosis [13–15]. Although other investigators have
failed to replicate this association [16, 17], it nevertheless
provides an intriguing insight into the mechanistic link
between TLR pathways and atheroma formation.This review
article aims to describe the immunological role of TLRs
in promoting the development of atherosclerosis, with a
primary focus on the function of TLR2, TLR4, and TLR9.
Pathophysiology of Atherosclerosis. Central to the develop-
ment and progression of atheromas is the interaction between
activated monocytes and oxidized LDL (oxLDL) leading
to formation of foam cells. Low density lipoprotein (LDL)
represents two-thirds of total cholesterol [18]. The American
College of Cardiology/American Heart Association define
hyperlipidemia associated with increased cardiovascular dis-
ease risk as LDL plasma levels above 70–189mg/dL (1.81–
4.89mmol/L) [19].Moreover, an LDL/HDL ratio greater than
3 is considered atherogenic [18]. Plasma LDL is transported
by apolipoprotein-B lipoprotein complexes in the circulation
(ApoB-LPs) such as ApoB-100. In vivo, LDL-C undergoes
oxidative modification resulting in the formation of oxLDL,
which has strong proinflammatory and immunogenic prop-
erties. [20, 21]. Endothelial activation ensues following the
lodging of oxLDL in the subendothelial matrix of the tunica
intima [22]. Here, oxLDL triggers a response akin to that
observed during chronic tissue injury, in that mononu-
clear leukocytes, primarily monocytes and lymphocytes,
are recruited to the “site of injury” where oxLDL lodges
[23, 24]. Tissue macrophages scavenge oxLDL and become
transformed into foam cells. These lipid-laden foam cells
form the basis of the initial lesion. The accumulation of
foam cells gives rise to fatty streaks [25]. Furthermore, as
the plaque evolves, intermediate lesions are formed, char-
acterised by smooth muscle cell (SMC) proliferation and
migration from the tunica media to the tunica intima. SMCs
also become lipid-laden. Late stages of plaque evolution
include atheromatous plaques and fibroatheromas [26]. In
atheromas, foam cells undergo apoptosis and accumulate,
forming a lipid-rich necrotic core [27]. Angiogenesis is evi-
dent in plaque development and its role is poorly understood.
Some authors postulate that angiogenesis is triggered by
cytokines secreted from activated macrophages to provide
monocytes that can differentiate into tissue macrophages,
to phagocytose the apoptotic foam cells [28]. Other authors
propose that angiogenesis in these lesions serves to perfuse
the hypoxic environment created by the cellular debris [29].
The consensus is that angiogenesis may set up a vicious
cycle whereby there is a continual supply of monocytes
which differentiate into tissue macrophages and become
transformed into foam cells as a result of oxLDL uptake. On
the other hand, fibroatheromas consist of extracellularmatrix
secreted by SMCs, and there is also evidence of calcified
deposits. This is the basis of the fibrous cap formation
[27]. In end-stage CAD, fibroatheromas may further evolve
into complicated unstable lesions with surface defects and
multiple necrotic cores. Complications from such lesions
include erosion, rupture, fissure, and ulceration, resulting
in various clinical manifestations, such as acute coronary
syndromes [26, 30].
Epidemiology of CAD. CAD remains a prevalent cause of
global mortality, accounting for an approximate 1.8 million
annual deaths in Europe alone, which translates to 20%
of total European mortality [31]. Low- and middle-income
countries in Eastern Europe and Central Asia are now the
most heavily affected by CAD. This is primarily due to the
fact that these regions constitute the majority of the world’s
population. Contributing to the shift in CAD epidemiology
is the increasing affluence in developing regions, including
Latin America, Sub-Saharan Africa, Middle East, and South
East Asia. The increasing urbanization, industrialization,
and adoption of Western-style lifestyles that follows from
economic growth impact negatively on cardiovascular mor-
tality and have extensive socioeconomic implications [32].
Furthermore, the shift in population demographics resulting
in increased life expectancy further compounds the clinical
and public health burden exerted by CAD, particularly in
Western countries [33].
2. TLR Signaling
TLRs are type 1 transmembrane glycoproteins comprised
of extracellular, transmembrane, and intracellular signaling
domains that are expressed either on the plasma mem-
brane or on intracellular endolysosomal compartments. The
cytoplasmic signaling domain is shared with that of the
interleukin-1 (IL-1) receptor (the toll/IL-1R domain, TIR),
and as a consequence of this homology TLRs activate
pathways shared with IL-1R [12]. Upon ligand binding, the
TLR signaling cascade is initiated by the TIR domain via
a number of cytoplasmic adapter molecules. These include
myeloid differentiation primary response protein (MyD88),
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TIR-domain-containing adaptor protein (TIRAP), andTRIF-
related adaptor molecule (TRAM) [34].
The MyD88 pathway is essential for all TLR signaling,
with exception of TLR3. MyD88 activates IL-1R associated
kinases (IRAKs), IRAK-1 and IRAK-4, and TNF-receptor
associated factor-6 (TRAF-6) [35, 36]. Consequently, recruit-
ment of a number of proteins activates a complex containing
TGF-𝛽-activated kinase 1 (TAK1), TAK1-binding protein-1
(TAB1), TAB2, and TAB3 [37]. The TAK1/TAB complex turn
leads to activation of both the MAPK and NF-𝜅B signaling
pathways [38]. These steps result in activation of a num-
ber of genes coding for proinflammatory cytokines and
chemokines, including TNF-𝛼, IL-1, and Il-6 [39].
TLR3 and TLR4 can also engage an MyD88-independent
signaling pathway [40].This requires TRIF andTRAMadapt-
er proteins that lead to phosphorylation of interferon regu-
latory factor 3 (IRF3) and NF-𝜅B transcription factors [41].
The major outcome of TRIF-dependent TLR4 signaling is
the production of type I interferons that have antiviral and
antiproliferative activity [42, 43].
The balance between MyD88-dependent and TRIF-
dependent TLR signaling is essential for proper immune
function. These two pathways show reciprocal interaction
and regulation. Wang et al. demonstrated that Nrdp1 (E3
ubiquitin ligase) inhibits the production of proinflammatory
cytokines but increases IFN-𝛽 production in TLR-activated
macrophages. This is achieved by suppressing the MyD88-
dependent activation of NF-𝜅B through ubiquitination of
MyD88 [44]. Conversely, Liu et al. showed that intracellular
MHC class II molecules in antigen presenting cells can acti-
vate both MyD88 and TRIF cascades, leading to production
of proinflammatory cytokines and interferons [45].
In addition to the activation of NF-𝜅B transcription fac-
tor in MyD88-dependent and MyD88-independent fashion,
TLR2 has been implicated in the stimulation of proapoptotic
pathways. Aliprantis et al. first demonstrated that bacterial
lipoproteins induce monocyte apoptosis in vitro [46]. Sub-
sequently they demonstrated that MyD88 is the common
mediator of TLR2-induced apoptosis and NF-𝜅B activation
and that TLR2 induces apoptosis through the FADD-caspase
pathway in a manner analogous to members of the TNFR
family [47, 48]. The in vivo relevance of TLR2 proapoptotic
activity in either reinforcing or terminating the inflammatory
response remains elusive, and its specific role in chronic
inflammatory processes is poorly understood.
2.1. TLR Ligands. TLRs are able to bind a wide range of both
endogenous and exogenous ligands. Primarily, they function
as receptors formolecular domains borne on bacterial or viral
pathogens. TLRs expressed on the plasma membrane recog-
nize cell-wall components of bacteria and fungi, while those
expressed on internal endolysosomal compartments bind
viral PAMPs. Specifically, TLR2 binds bacterial lipoproteins,
and TLR4 is primarily activated by bacterial lipopolysaccha-
ride and TLR9 by unmethylated CpG nucleotide sequences
[12]. In addition to exogenous ligands of microbial origin,
TLRs are able to bind a wide range of endogenous ligands.
These endogenous ligands are host-derived molecules that
stimulate TLR signaling in the absence of infection, and they
have been extensively reviewed elsewhere [49, 50]. Endoge-
nous ligands include various extracellular matrix compo-
nents, including fibronectin [51], fibrinogen [52], hyaluronic
acid derivatives [53], heat shock proteins [54], andminimally
oxidized low density lipoprotein [55].These ligands are either
actively released by cells at sites of injuy or passively released
by cells damaged from inflamed tissues.
The evolving atherosclerotic plaque is a site of matrix
turnover, tissue remodeling, and cell necrosis and hence
contains a number of endogenous TLR ligands. Of particular
interest are heat shock proteins (HSPs), which have been
identified as powerful activators of innate immune function.
Various investigators report that HSP60 induces a proinflam-
matory response in a TLR2 and TLR4 dependent fashion
[56–58]. However, this hypothesis has been extensively chal-
lenged. Investigations showed that contamination by LPS in
the HSP preparations is responsible for the observed TLR4
activation [59, 60]. LPS is a powerful inducer of TLR activa-
tion even inminute quantities, and LPS contamination results
from the production of recombinant HSP in Escherichia coli.
TLR signaling cascades can be activated by a broad
range of host-derived molecules in the absence of exogenous
infection, and this plays a central role in the development
and progression of atherosclerosis. The subsequent sections
of this review focus on the roles of TLR2, TLR4, and TLR9 in
the pathogenesis of atherosclerosis. Figure 1 outlines the key
mechanisms from functional and animal studies implicating
TLR2 and TLR4 in atherosclerosis.
2.2. TLR2 and Atherosclerosis. TLR2 is a cell surface receptor
that binds a wide range of microbial components, such as
gram-positive-derived lipoteichoic acid, bacterial lipopro-
teins, and zymosan [61]. It is expressed in a number of
immune cells, the endothelium, and epithelial cells [62].
TLR2 has a unique ability to form functional heterodimers
with either TLR1 or TLR6 resulting in relatively broad ligand
specificity [63]. TLR2 expression, along with that of TLR1 and
TLR4, is markedly increased in endothelial cells overlying
atheromas [64]. Furthermore, endothelial TLR2 expression
and activation may occur at areas of turbulent blood flow,
such as the areas of lesion predilection within the aortic tree
and heart. In vitro experiments using human coronary artery
endothelial cells exposed to laminar blood flow showed lower
levels of TLR2 expression when compared to endothelial cells
exposed to static or turbulent flow [65]. Laminar flow at
or above 0.5N/m2 inhibits endothelial TLR2 expression via
protein kinase CK2, which phosphorylates a transcription
factor known as specificity protein-1 (SP1). This prevents
SP1 binding to the TLR2 promoter, thereby reducing TLR2
expression. In doing so, flow suppression of TLR2 expression
is considered to be atheroprotective [65]. Mullick et al.
showed that, in atherosclerosis-susceptible LDLR-deficient
(LDLR−/−) mice, complete deficiency of TLR2 leads to a
reduction in atherosclerosis, whereas expression of TLR2
only on bone marrow derived cells has no impact on
atherosclerosis [66]. This experiment showed that TLR2
expression on non-bone marrow derived cells, such as vas-
cular endothelium, at sites of nonlaminar flow contributes to
the atherosclerosis. Furthermore, the authors showed that on
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Figure 1: An overview of the proatherogenic effects of TLR2 and TLR4 compared to antiatherogenic effects of TLR9.
administration of Pam3CSK4 (a synthetic TLR2/TLR1 ago-
nist), atherosclerotic burden was dramatically increased in
LDLR−/− mice. The proatherogenic effect of Pam3CSK4 was
not observed in LDLR−/− mice with complete TLR2 defi-
ciency or in LDLR−/− mice with a deficiency of TLR2 only in
bone marrow derived cells. This finding reinforces the role of
TLR2 in promoting atherosclerosis through its action in cells
of non-bone marrow origin.
Further investigations by Mullick et al. using LDLR−/−
mice showed that aortic endothelial cell TLR2 expression was
confined to areas of nonlaminar flow, specifically in the lesser
curvature of the aorta, and that hyperlipidemia increases
endothelial TLR2 expression [67]. Furthermore, the authors
generated chimeric mice with green fluorescent protein
(GFP) expression in BM derived cells (BMGFP+). Bone mar-
row reconstitution of LDLR−/− and LDLR−/−TLR2−/− mice
with BMGFP+ cells showed that hyperlipidemia increases
lesser curvature BMGFP+ leukocyte accumulation, lipid
accumulation, and foam cell generation, whereas hyperlipi-
demic double mutant BMGFP+LDLR−/−TLR2−/− mice had
reduced lesser curvature atherogenic activity. This study
showed that endothelial TLR2 expression is linked to early
atherosclerosis in murine models.
The role of TLR2 in atherosclerosis has been reinforced
by other studies. Using ApoE−/− atherosclerotic mice Schon-
eveld et al. showed that exogenous TLR2 activation increases
atherosclerotic plaque formation and plaque-media ratio.
TLR2 is involved not only in the initial intimal lesion
formation but also in development of occlusive disease [68].
Furthermore, TLR2 promotes vascular smooth muscle cell
(VSMC) migration from tunica media to the intima in an
IL-6 dependent manner [69]. Genetic deficiency of TLR2
reduces diet-induced atherosclerosis in ApoE+/− mice [70],
and TLR2 expression and activation regulates the inflam-
matory processes and ROS production following vascular
injury in mouse models [71]. Aside from the involvement
of TLR2 in atheroma development, evidence shows that
TLR2 contributes to coronary endothelial dysfunction after
ischemia/reperfusion by activating neutrophils and free rad-
ical production [72].
Scavenger receptors such as the CD36 coreceptor have
been linked to activation of TLR2 [52]. CD36 functions in the
recognition of various endogenous ligands, including oxLDL
and the uptake of fatty acids. Nonetheless, even though TLR2
participates in the immune response to oxLDL, it is not a
primary culprit in formation of foam cells unlike TLR4 and
CD36 [73].
Other ligands implicated in TLR2 activation include
high-mobility group box 1 protein (HMGB1).This is a nuclear
transcription factor secreted by macrophages, monocytes,
and dendritic cells that is expressed in atherosclerotic lesions
[74]. It binds to TLR2 and triggers release of proinflammatory
cytokines [75]. HMGB1 also has proatherogenic effects and
stimulates macrophage migration in atherosclerotic lesions
[55].
Members of Wnt family of glycoproteins such as Wnt5a
have been reported to be coexpressed with TLR2 and TLR4
in macrophage rich regions of more advanced staged athero-
matous plaques [76]. oxLDL can induce mRNA expression of
Wnt5a, which correlates with the severity of atherosclerotic
lesions in human studies [77]. Wnt5a has been implicated in
the regulation of cholesterol transport inmousemacrophages
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[78]. Recently, Wnt5a pathways have shown playing a critical
role in foam cell formation and oxLDL uptake [79]. The
complex role of Wnt5a pathways in atherosclerosis has
been extensively reviewed by Bhatt and Malgor [80]. Taken
together, these studies highlight the elaborate signaling
pathways involving TLR2 and its important role in driving
atherogenesis.
2.3. TLR4 and Atherosclerosis. TLR4 resides in the plasma
membrane, where it recognizes a number of exogenous
ligands and activates a series of inflammatory cascades in an
NK-𝜅B-dependent fashion [81]. Several lines of clinical and
experimental evidence support its role in the pathogenesis
of atheromas. Human studies showed that CD14+ monocyte
TLR4 expression is increased in unstable angina and acuteMI
compared to control and stable angina groups [82, 83]. Satoh
et al. showed that activation of TLR4 is associated with heart
failure followingMI [84]. Conversely, Tapp et al. showed that
MI is associated with increased numbers of TLR4+monocyte
subsets, but not with higher TLR4 expression by individual
monocytes [85].
Atherosclerotic plaque cells, in a manner analogous to
TLR2, express TLR4 [64]. TLR4 levels are upregulated by
oxLDL andHowell et al. showed that inmurinemodels TLR4
is necessary for the oxLDL-induced macrophage differentia-
tion into foam cells [86]. Similarly, TLR4 is a critical medi-
ator in oxLDL-induced inflammatory cytokine expression
in vascular smooth muscle cells [87]. Minimally modified
LDL (a subtype of oxLDL that is essential for atherosclerosis)
induces ROS production and macrophage cytoskeletal rear-
rangements in a TLR4 dependent and MyD88-independent
manner [55, 88]. The spleen tyrosine kinase SYK binds to
the cytoplasmic domain of TLR4 and mediates macrophage
activation, membrane ruffling, macropinocytosis, lipid accu-
mulation, and their consequent transformation into lipid-
laden foam cells [89, 90].
Further experimental evidence from loss-of-function
animal models supports the role of TLR4 in atherosclerosis.
Atherosclerosis-proneApoE−/−micewith deficiency of TLR4
or MyD88 show attenuation in atherosclerosis develop-
ment through decreased macrophage recruitment [91, 92].
Higashimori et al. showed that TLR4 contributes to early-
stage intimal foam cell accumulation at lesion-prone aortic
sites in ApoE−/− TLR4−/− mice, with a 75% reduction in inti-
mal lipid levels compared toApoE−/− controls [93].This study
also showed that TLR4 is a more powerful contributor to
foam cell formation than TLR2. Coenen et al. demonstrated
thatmice lackingmacrophage TLR4 expression have reduced
atherosclerotic lesion size when fed low-fat diets, despite no
observed difference in body composition and plasma lipids
[94]. TLR4 is also involved in outward arterial remodeling.
This process compensates for loss of the vascular lumen
due to plaque accumulation and involves collagen matrix
degradation by matrix metalloprotease-9 (MMP-9), which is
activated by TLR4 [95]. Disordered arterial remodeling con-
tributes to atherosclerosis and vascular restenosis. TLR4−/−
mice show no outward arterial remodeling in carotid artery
ligation and femoral artery cutoff models [96].
In addition to the established function of TLR4 in ath-
eroma development, it also plays a critical role in the
progression and eventual rupture of atherosclerotic plaques
leading to the formation of occlusive thrombus. Ishikawa et
al. demonstrated an increased expression of TLR4, but not
TLR2, in ruptured human coronary atherosclerotic plaques,
with TLR4 immunostaining observed in the infiltrating
macrophages [97]. Recent literature further implicates TLR4
in plaque instability. Gargiulo et al. showed that specific com-
ponents of oxLDL that accumulate in atheromas enhance the
release of proinflammatory cytokines and upregulateMMP-9
in a TLR4/NF-𝜅B-dependent fashion [98]. This investigation
directly implicates the role of lipid derivatives as endogenous
TLR4 ligands that contribute to matrix breakdown.
The extracellular matrix (ECM) is a key player in the
progression of atherosclerotic disease, and several studies
have described the structural alterations that develop dur-
ing atherosclerosis [83, 99]. Chronically inflamed tissues
express extracellular matrix (ECM) proteins that regulate the
migration of leukocytes and other immune cells to sites of
injury. While healthy human endothelium rests on an ECM
composed of collagen IV and laminin, the ECMof atheroscle-
rotic vessels contains abundant fibronectin in both human
and mouse models [100, 101]. Fibronectin occurs in two
forms generated by alternative splicing, plasma fibronectin
(pFN) and cellular fibronectin (cFN). pFN is a soluble dimer
secreted by hepatocytes. cFN is expressed in the ECM of
various tissues and is a multimer that forms fibrils and
contains extra domains A and B (EDA and EDB) [102]. cFN is
synthesised by vascular smooth muscle and endothelial cells.
The extra domainA in fibronectin (EDA+FN) is implicated in
a number of biological processes, including atherosclerosis.
Deletion of the alternatively spliced EDA exon reduces the
number and size of atherosclerotic lesions in ApoE null
mice [103, 104]. In vitro studies also suggested that the FN
EDA domain activates TLR4 [51]. Further investigations
using ApoE null mice with either constitutive expression
or knockout of the fibronectin EDA domain showed that
EDA+FN promotes progression of atherosclerosis through a
mechanism that is partially dependent on TLR4 [105]. The
authors showed that EDA+FN drives macrophage recruit-
ment into developing plaques through TLR4 signaling. Com-
parably, Prakash et al. showed that platelet TLR4 facilitates
the prothrombotic effects of cellular EDA+FN on platelet
aggregation and arterial thrombosis [106]. EDA+FN mice
lacking platelet TLR4 showed decreased thrombus formation
and a slower thrombus growth rate compared with con-
trol mice expressing platelet TLR4, further highlighting the
proatherogenic effect of the FN-TLR4 interaction.
2.4. TLR9 and Atherosclerosis. While TLR2 and TLR4 are
expressed on the cell surface, TLR9 colocalises to the en-
doplasmic reticulum in various cell types, including B-cells,
macrophages, dendritic cells, and plasma cells [107]. In the
ER, TLR9 is able to detect and bind unmethylated oligode-
oxynucleotide CpG motifs in microbial DNA sequences and
trigger inflammatory responses [108]. Unmethylated CpG
sequences are rare in eukaryotic genomes but abundant in
prokaryotes.
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Apart from its role in the recognition of bacterial DNA,
TLR9 has been closely linked with the development of
atherosclerotic lesions, since it is activated by CpG motifs
in nucleic acids that are released during vascular necro-
sis. Activation of TLR9 stimulates the transformation of
murine macrophages into foam cells in an NF-𝜅B- and
IRF7-dependent manner [109]. This process is inhibited by
the activation of liver x-receptors, which are transcriptional
regulators of lipid and carbohydrate metabolism [110].
In addition, activation of TLR9 via CpG-containing
nucleotide sequences in plasmacytoid dendritic cells stim-
ulates interferon-𝛼 (INF-𝛼) secretion and increases the
cytotoxic activity of CD4+ T-cells towards vascular smooth
muscle cells [111].
However, some investigators have suggested that TLR9 is
protective against atherosclerosis. In vitro activation of TLR9
stimulates interleukin-10 (IL-10) production, which in turn
inhibits the expression of INF-𝛼 secreted by plasma dendritic
cells and inhibits CD4+ CD25+ T-cell proliferation [112, 113].
Loss-of-function animal models have been used to further
elucidate the role of TLR9 in atheroma. Koulis et al. used a
double knockout mouse model lacking both TLR9 and ApoE
to compare aortic sinus atherosclerotic lesion development.
The investigators showed a 33% increase in lipid deposition
and atherosclerotic plaque size in ApoE−/−/TLR9−/− mice
compared to ApoE−/− mice [114]. Furthermore, there was
significant accumulation ofmacrophages, dendritic cells, and
INF-𝛼 in vasculature of ApoE−/−/TLR9−/− mice compared
to control animals. Loss of TLR9 function thus exacerbates
atherosclerosis in ApoE null mice exposed to a high fat diet.
Other investigators have reported contradictory findings.
Pharmacologic inactivation of TLR9 pathways in animal
models results in a reduction in atherosclerotic lesion gen-
eration in ApoE−/− mice and reduced instability of vulner-
able plaques [115]. Ma et al. showed that inactivation of
TLR9 using immunoregulatory oligodeoxynucleotides such
as IRS869 reduces plaque burden and shunts the activities of
proinflammatory macrophages (M1) into anti-inflammatory
macrophages (M2). Krogmann et al. investigated the effect of
administering intravenous ODN1826 (type B oligodeoxynu-
cleotide that activates TLR9).They showed that stimulation of
TLR9 impairs reendothelialization following acute vascular
injury and increases plaque development in ApoE−/− mice
[116]. Nonetheless, pharmacologic TLR9 activation did not
alter the endothelium-dependent vasodilation, suggesting
that TLR9 activation only affects the regenerative process but
not the vasoactive function of endothelial cells. Both pro- and
antiatherosclerotic effects of TLR9 have been described. One
possible explanation for the discrepancies between the inves-
tigations reported by Krogmann et al. includes differences
in the oligodeoxynucleotide dosage regime, as development
of atherosclerosis requires chronic sustained inflammatory
trigger [116]. Further investigations are needed to further
define the role of TLR9 agonists in atherosclerotic disease.
2.5. Regulatory T-Cells and TLR Signaling in Atherosclerosis.
Atherosclerosis is a highly complex process that involves
multiple signaling cascades and a wide variety of cell types,
including monocytes, macrophages, VSMCs, and various
subtypes of T lymphocytes. T-cell subtypes exert differing
effects on atherogenesis. Th1 cells are proatherogenic while
Th2 and Tregs (T-regulatory cells) have atheroprotective
effects [117, 118]. The function of different T-cell subtypes in
atherosclerosis has been recently reviewed elsewhere [119,
120]. Of particular interest is the link between Tregs and
atherosclerosis. Subramanian et al. investigated the role
of monocyte-derived CD11c+ dendritic cells. In this study,
LDLR−/− mice were reconstituted with bone marrow cells
where CD11c+ cells lacked the TLR adaptor MyD88 [121].
This decreases their ability to activate T-effector cells and
was expected to produce a decrease in atherosclerosis [122].
On the contrary, the study demonstrated an increase in
aortic root atheroma size and monocyte infiltration, with
no differences in lipoprotein levels. This effect was due to
the loss of Treg-mediated suppression of MCP-1, and the
data demonstrated the atheroprotective role of Treg cells in
murine models. It also provides interesting insight into the
function of TLRs at the crossroads of innate and adaptive
immunity in atherosclerosis, which might be useful in the
development of novel therapeutic strategies [123].
2.6. TLR Polymorphism in Atherosclerosis. Further evidence
supporting the role of TLRs in atheroma development
comes from genetic association studies. Most studies have
focused on two missense polymorphism types in TLR4,
Asp299Gly and Thr399Ile, and conflicting associations have
been reported. Some investigators reported a reduced risk
of atherosclerosis in carriers of the Asp299Gly TLR4 poly-
morphism [124], which was not reproduced in other inves-
tigations [125]. Other case-control candidate genes have
identified an association between the TLR4 polymorphism
and acute myocardial infarction, with a reduced incidence
of cardiovascular events in the 299GLy allele [126, 127].
However, a meta-analysis by Koch et al. showed no asso-
ciation between TLR4 variants and myocardial infarction
in a Caucasian cohort [128]. Population-specific differences
in risk allele frequency possibly account for the different
associations reported in the literature [129, 130].
3. Conclusion
TLRs form part of the innate arm of the immune system
where they play an integral role in defense mechanisms
against pathogens. They are expressed on a number of
immune cells including macrophages, monocytes, and den-
dritic cells. TLRs distinguish between host molecules and
PAMPs upon binding to the ligand and thereby trigger
inflammatory response via NK-𝜅B pathways. MyD88 plays a
critical role in TLR signaling. MyD88 deficiency in myeloid
cells has been shown to inhibit macrophage recruitment and
activation of the M1 system. In vivo and ex vivo studies
have linked MyD88-dependent growth factors produced by
endothelial cells to initiating inflammation and development
of atherosclerosis by priming the monocytes in arterial
and adipose tissues to differentiate into M1-proinflammatory
macrophages instead of M2 anti-inflammatory macropha-
ges.
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Different subtypes of TLRs are involved in different
aspects of inflammatory response. TLR2 andTL4 are strongly
implicated in atheroma development and progression, lead-
ing to coronary artery disease.This is evidenced by a number
of in vitro and animal studies using atherosclerosis-prone
LDLR or ApoE deficient mice. Moreover, the development of
atherosclerotic plaques often requires more than just TLRs,
and coreceptors such as CD36 have been linked to TLR2
activation and inducing atherosclerotic change. Even though
TLR2 and TLR4 are often labelled as “atherogenic promot-
ers,” they are not considered as the primary culprit behind
certain inflammatory changes such as formation of foam
cells and generation of oxLDL. Furthermore, the presence
of TLR4 in unstable plaques suggests that it is a major
driver of CAD progression. TLR4 upregulates matrix met-
allopeptidases such as MMP-9 which makes plaques prone
to rupture. The precise function of TLR9 in atherosclerosis
is yet to be defined, with conflicting studies reporting both
proatherogenic and antiatherogenic effects. Clearly, TLRs
are promising therapeutic targets and possible biomarker
candidates for a wide range of pathologies, but further studies
are required in order to fully define their function.
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